

Inborn Metabolic Diseases

Diagnosis and Treatment

Bearbeitet von
Jean-Marie Saudubray, Georges van den Berghe, John H Walter

5th Edition. 2011. Buch. XXVIII, 656 S. Hardcover
ISBN 978 3 642 15719 6
Format (B x L): 19,3 x 26 cm
Gewicht: 1633 g

[Weitere Fachgebiete > Medizin > Klinische und Innere Medizin > Stoffwechselstörungen](#)

schnell und portofrei erhältlich bei


DIE FACHBUCHHANDLUNG

Die Online-Fachbuchhandlung bech-shop.de ist spezialisiert auf Fachbücher, insbesondere Recht, Steuern und Wirtschaft. Im Sortiment finden Sie alle Medien (Bücher, Zeitschriften, CDs, eBooks, etc.) aller Verlage. Ergänzt wird das Programm durch Services wie Neuerscheinungsdienst oder Zusammenstellungen von Büchern zu Sonderpreisen. Der Shop führt mehr als 8 Millionen Produkte.

Contents

I Diagnosis and Treatment: General Principles

1	Clinical Approach to Inborn Errors of Metabolism in Pediatrics	3
	<i>Jean-Marie Saudubray</i>	
1.1	Classification	4
1.1.1	Pathophysiology	4
1.1.2	Clinical Presentation	5
1.2	Antenatal Symptoms	5
1.3	Symptoms in the Neonatal Period and Early Infancy (<1 year)	6
1.3.1	Clinical Presentations	6
1.3.2	Metabolic Derangements and Diagnostic Tests	12
1.4	Metabolic Emergencies from Late Infancy to Adolescence	15
1.4.1	Clinical Presentations	15
1.4.2	Metabolic Derangements and Diagnostic Tests	22
1.5	Chronic and Progressive Neurological Symptoms (Mental Retardation, Developmental Delay, Epilepsy, Neurological Deterioration and Psychiatric Symptoms)	27
1.5.1	Diagnostic Approach to Neurological and Mental Deterioration Related to Age	28
1.5.2	Diagnostic Approach to Neuromental Deterioration According to Neurophysiological and Neuroradiological Signs	36
1.6	Specific Organ Signs and Symptoms	41
1.6.1	Cardiology	41
1.6.2	Dermatology	41
1.6.3	Dysmorphology, Malformations, Dysplasia	43
1.6.4	Endocrinology	43
1.6.5	Gastroenterology	44
1.6.6	Haematology	45
1.6.7	Hepatology	48
1.6.8	Immunology	49
1.6.9	Myology	49
1.6.10	Nephrology	49
1.6.11	Neurology and Psychiatry	49
1.6.12	Ophthalmologic Signs	49
1.6.13	Osteology	51
1.6.14	Pneumology	51
1.6.15	Psychiatry	52
1.6.16	Rheumatology	52

1.6.17	Stomatology	52
	References	52

2 Inborn Errors of Metabolism in Adults: A Diagnostic Approach to Neurological and Psychiatric Presentations

Frédéric Sedel

2.1	Introduction	56
2.2	Differences Between Paediatric and Adult Phenotypes	56
2.3	General Approach to IEM in Adulthood	58
2.3.1	Energy Metabolism Defects	59
2.3.2	Disorders of Lipid Metabolism	60
2.3.3	Intoxication Syndromes	60
2.3.4	Disorders of Neurotransmitter Metabolism	60
2.3.5	Metal Storage Disorders	60
2.4	Specific Approaches to Neurometabolic Presentations in Adults	60
2.4.1	Encephalopathies/Comas	60
2.4.2	Strokes and Pseudo-strokes	61
2.4.3	Movement Disorders	61
2.4.4	Peripheral Neuropathies	64
2.4.5	Leukoencephalopathies	64
2.4.6	Epilepsy	64
2.4.7	Psychiatric Disorders	66
2.4.8	Spastic Paraparesis	69
2.4.9	Cerebellar Ataxia	69
2.4.10	Myopathy	70
2.4.11	Others	72
	References	74

3 Newborn Screening for Inborn Errors of Metabolism

Bridget Wilcken, Piero Rinaldo, Dietrich Matern

3.1	Introduction	76
3.2	General Aspects of Newborn Screening	76
3.2.1	Aims and Criteria	76
3.2.2	Sensitivity, Specificity and Positive Predictive Value	76
3.2.3	Technical Aspects of Newborn Screening Tests	77
3.2.4	Range of Possibilities from Early Detection	78
3.2.5	Follow-up	78
3.3	Screening for Individual Inborn Errors of Metabolism	82
3.3.1	Aminoacidopathies	82
3.3.2	Galactosaemias	83
3.3.3	Organic Acid Disorders	83

3.3.4	Fatty Acid Oxidation Disorders	84
3.3.5	Lysosomal Storage Disorders	84
3.3.6	Other Conditions	85
	References	85

4 Diagnostic Procedures: Functional Tests and Post-mortem Protocol87 *Guy Touati, Fanny Mochel, Daniel Rabier*

4.1	Introduction	88
4.2	Basal Investigation	88
4.2.1	Amino and Organic acids Analyses	88
4.2.2	Metabolic Profile over the Course of the Day	88
4.3	In Vitro ¹ H-NMR Spectroscopy of Body Fluids	95
4.4	Functional Tests	96
4.4.1	Fasting Test	96
4.4.2	Glucose Loading Test	98
4.4.3	Protein and Allopurinol Loading Tests	98
4.4.4	Exercise Test	99
4.5	Post-mortem Protocol	100
4.5.1	Cells and Tissues for Enzyme Assays	100
4.5.2	Cells and Tissues for Chromosome and DNA Investigations	100
4.5.3	Skin Fibroblasts	100
4.5.4	Body Fluids for Chemical Investigations	101
4.5.5	Autopsy	101
	References	101

5 Emergency Treatments 103 *Carlo Dionisi-Vici, Hélène Ogier de Baulny*

5.1	General Principles	104
5.1.1	Supportive Care	104
5.1.2	Nutrition	104
5.1.3	Specific Therapies	104
5.1.4	Extracorporeal Procedures for Toxin Removal	105
5.2	Emergency Management of Particular Clinical Presentations	105
5.2.1	Neurological Deterioration	105
5.2.2	Liver Failure	108
5.2.3	Neonatal Hypoglycaemia	108
5.2.4	Cardiac Failure	109
5.2.5	Primary Hyperlactataemia	109
5.2.6	Intractable Convulsions	109
5.3	Final Considerations	110
	References	110

II Disorders of Carbohydrate Metabolism

6 The Glycogen Storage Diseases and Related Disorders 115 *Pascal Laforêt, David A. Weinstein, G. Peter, A. Smit*

6.1	Liver Glycogenoses	117
6.1.1	Glycogen Storage Disease Type I (Glucose-6-Phosphatase or Translocase Deficiency)	117
6.1.2	Glycogen Storage Disease Type III (Debranching Enzyme Deficiency)	122
6.1.3	Glycogen Storage Disease Type IV (Branching Enzyme Deficiency)	123
6.1.4	Glycogen Storage Disease Type VI (Glycogen Phosphorylase Deficiency)	125
6.1.5	Glycogen Storage Disease Type IX (Phosphorylase Kinase Deficiency)	125
6.1.6	Glycogen Storage Disease Type 0 (Glycogen Synthase Deficiency)	126
6.2	Muscle and Cardiac Glycogenoses	127
6.2.1	GSDs With Exercise Intolerance Without Cardiac Involvement	127
6.2.2	GSDs with Cardiac Involvement	130
6.3	Brain Glycogenoses	133
6.3.1	Lafora Disease (Neuronal Laforin/Malin Defects)	133
6.3.2	Adult Polyglucosan Body Disease (Astrocytes Branching Enzyme Deficiency)	134
	References	134

7 Disorders of Galactose Metabolism 141 *Gerard T. Berry, John H. Walter*

7.1	Galactose-1-Phosphate Uridyltransferase Deficiency	143
7.1.1	Clinical Presentation	143
7.1.2	Metabolic Derangement	143
7.1.3	Genetics	144
7.1.4	Diagnostic Tests	144
7.1.5	Treatment and Prognosis	144
7.2	Uridine Diphosphate-Galactose 4'-Epimerase Deficiency	147
7.2.1	Clinical Presentation	147
7.2.2	Metabolic Derangement	147
7.2.3	Genetics	147
7.2.4	Diagnostic Tests	147
7.2.5	Treatment and Prognosis	147
7.3	Galactokinase Deficiency	148
7.3.1	Clinical Presentation	148

7.3.2	Metabolic Derangement	148	10	Persistent Hyperinsulinaemic Hypoglycaemia	167
7.3.3	Genetics	148		<i>Pascale de Lonlay, Jean-Marie Saudubray</i>	
7.3.4	Diagnostic Tests	148	10.1	Clinical Presentation	169
7.3.5	Treatment and Prognosis	148	10.2	Metabolic Derangement	169
7.4	Fanconi-Bickel Syndrome	149	10.3	Genetics	169
7.5	Portosystemic Venous Shunting and Hepatic Arteriovenous Malformations	149	10.4	Diagnostic Tests	170
	References	149	10.4.1	Diagnostic Criteria	170
8	Disorders of the Pentose Phosphate Pathway	151	10.4.2	Differentiation of Focal from Diffuse Forms	171
	<i>Mirjam M.C. Wamelink, Vassili Valayannopoulos, Cornelis Jakobs</i>		10.5	Treatment and Prognosis	171
8.1	Ribose-5-Phosphate Isomerase Deficiency	153	10.5.1	Medical Treatment	171
8.1.1	Clinical Presentation	153	10.5.2	Surgical Treatment	171
8.1.2	Metabolic Derangement	153	10.5.3	Prognosis	172
8.1.3	Genetics	153	10.6	Conclusion	172
8.1.4	Diagnostic Tests	153		References	172
8.1.5	Treatment and Prognosis	153	11	Disorders of Glucose Transport	175
8.2	Transaldolase Deficiency	153		<i>René Santer, Jörg Klepper</i>	
8.2.1	Clinical Presentation	153	11.1	Congenital Glucose/Galactose Malabsorption (SGLT1 Deficiency)	177
8.2.2	Metabolic Derangement	154	11.1.1	Clinical Presentation	177
8.2.3	Genetics	154	11.1.2	Metabolic Derangement	177
8.2.4	Diagnostic Tests	155	11.1.3	Genetics	177
8.2.5	Treatment and Prognosis	155	11.1.4	Diagnostic Tests	177
	References	155	11.1.5	Treatment and Prognosis	178
9	Disorders of Fructose Metabolism	157	11.2	Renal Glucosuria (SGLT2 Deficiency)	178
	<i>Beat Steinmann, René Santer</i>		11.2.1	Clinical Presentation	178
9.1	Essential Fructosuria	159	11.2.2	Metabolic Derangement	178
9.1.1	Clinical Presentation	159	11.2.3	Genetics	178
9.1.2	Metabolic Derangement	159	11.2.4	Diagnostic Tests	178
9.1.3	Genetics	159	11.2.5	Treatment and Prognosis	178
9.1.4	Diagnosis	159	11.3	Glucose Transporter Deficiency Syndrome (GLUT1 Deficiency)	178
9.1.5	Treatment and Prognosis	159	11.3.1	Clinical Presentation	178
9.2	Hereditary Fructose Intolerance	159	11.3.2	Metabolic Derangement	179
9.2.1	Clinical Presentation	159	11.3.3	Genetics	179
9.2.2	Metabolic Derangement	160	11.3.4	Diagnostic Tests	179
9.2.3	Genetics	160	11.3.5	Treatment and Prognosis	179
9.2.4	Diagnosis	161	11.4	Fanconi-Bickel Syndrome (GLUT2 Deficiency)	180
9.2.5	Differential Diagnosis	161	11.4.1	Clinical Presentation	180
9.2.6	Treatment and Prognosis	161	11.4.2	Metabolic Derangement	180
9.3	Fructose-1,6-Bisphosphatase Deficiency	162	11.4.3	Genetics	180
9.3.1	Clinical Presentation	162	11.4.4	Diagnostic Tests	180
9.3.2	Metabolic Derangement	162	11.4.5	Treatment and Prognosis	181
9.3.3	Genetics	163	11.5	Arterial Tortuosity Syndrome (GLUT10 Deficiency)	181
9.3.4	Diagnosis	163	11.5.1	Clinical Presentation	181
9.3.5	Differential Diagnosis	164	11.5.2	Metabolic Derangement	181
9.3.6	Treatment and Prognosis	164	11.5.3	Genetics	181
	References	164	11.5.4	Treatment and Prognosis	181
				References	181

III Disorders of Mitochondrial Energy Metabolism

12 Disorders of Pyruvate Metabolism and the Tricarboxylic Acid Cycle 187	12.9.3 Diagnostic Tests 197
<i>Linda J. De Meirleir, Michèle Brivet, Angeles Garcia-Cazorla</i>	12.9.4 Genetics 197
12.1 Pyruvate Carboxylase Deficiency 189	12.9.5 Treatment and Prognosis 198
12.1.1 Clinical Presentation 189	12.10 Protein-bound lipid acid defect 198
12.1.2 Metabolic Derangement 189	References 198
12.1.3 Genetics 190	
12.1.4 Diagnostic Tests 190	
12.1.5 Treatment and Prognosis 190	
12.2 Phosphoenolpyruvate Carboxykinase Deficiency 191	
12.3 Pyruvate Dehydrogenase Complex Deficiency ... 192	13 Disorders of Mitochondrial Fatty Acid Oxidation and Related Metabolic Pathways .. 201
12.3.1 Clinical Presentation 192	<i>Andrew A.M. Morris, Ute Spiekerkoetter</i>
12.3.2 Metabolic Derangement 192	13.1 Introduction 203
12.3.3 Genetics 193	13.2 Clinical Presentations 203
12.3.4 Diagnostic Tests 193	13.2.1 Fatty Acid Transport Defects 203
12.3.5 Treatment and Prognosis 194	13.2.2 Carnitine Cycle Defects 203
12.4 Dihydropyruvate Dehydrogenase Deficiency ... 194	13.2.3 β-Oxidation Defects 205
12.4.1 Clinical Presentation 194	13.2.4 Electron Transfer Defects 206
12.4.2 Metabolic Derangement 194	13.3 Metabolic Derangement 207
12.4.3 Genetics 194	13.4 Genetics 207
12.4.4 Diagnostic Tests 194	13.5 Diagnostic Tests 208
12.4.5 Treatment and Prognosis 194	13.5.1 Abnormal Metabolites 208
12.5 2-Ketoglutarate Dehydrogenase Complex Deficiency 195	13.5.2 In Vitro Studies 210
12.5.1 Clinical Presentation 195	13.5.3 Fasting Studies 210
12.5.2 Metabolic Derangement 195	13.5.4 Prenatal Diagnosis 210
12.5.3 Genetics 195	13.5.5 Newborn Screening 211
12.5.4 Diagnostic Tests 195	13.6 Treatment and Prognosis 211
12.5.5 Treatment and Prognosis 195	13.6.1 Management of Acute Illness 211
12.6 Fumarate Deficiency 195	13.6.2 Long-term Dietary Management 211
12.6.1 Clinical Presentation 195	13.6.3 Drug Treatment 212
12.6.2 Metabolic Derangement 196	13.6.4 Monitoring 212
12.6.3 Genetics 196	13.6.5 Prognosis 212
12.6.4 Diagnostic Tests 196	13.7 Related Defects 214
12.6.5 Treatment and Prognosis 196	13.7.1 Defects of Leukotriene (LT) Metabolism 214
12.7 Succinate Dehydrogenase Deficiency 196	13.7.2 Sjögren-Larsson Syndrome 214
12.7.1 Clinical Presentation 196	References 214
12.7.2 Metabolic Derangement 196	
12.7.3 Genetics 197	14 Disorders of Ketogenesis and Ketolysis 217
12.7.4 Diagnostic Tests 197	<i>Andrew A.M. Morris</i>
12.7.5 Treatment and Prognosis 197	14.1 Clinical Presentation 219
12.8 Other Krebs Cycle Disorders 197	14.1.1 Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency 219
12.9 Pyruvate Transporter Defect 197	14.1.2 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency 219
12.9.1 Clinical Presentation 197	14.1.3 Succinyl-CoA 3-Oxoacid CoA Transferase Deficiency 219
12.9.2 Metabolic Derangement 197	14.1.4 Mitochondrial Acetoacetyl-CoA Thiolase Deficiency 219
	14.2 Metabolic Derangement 220
	14.3 Genetics 220
	14.4 Diagnostic Tests 220
	14.4.1 Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency 220
	14.4.2 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency 220

14.4.3	Succinyl-CoA 3-Oxoacid CoA Transferase Deficiency	220
14.4.4	Mitochondrial Acetoacetyl-CoA Thiolase Deficiency	221
14.4.5	Prenatal Diagnosis	221
14.5	Treatment and Prognosis	221
14.6	Cytosolic Acetoacetyl-CoA Thiolase Deficiency	221
	References	222
15	Defects of the Respiratory Chain	223
	<i>Arnold Munnich, Agnès Rötig, Marlène Rio</i>	
15.1	Clinical Presentation	224
15.1.1	Fetuses	226
15.1.2	Neonates	226
15.1.3	Infants	226
15.1.4	Children and Adults	227
15.2	Metabolic Derangement	227
15.3	Genetics	228
15.3.1	Mitochondrial DNA Mutations	229
15.3.2	Large-scale mtDNA Rearrangements	229
15.3.3	Nuclear DNA Mutations	229
15.3.4	Genetic Counselling and Prenatal Diagnosis	231
15.4	Diagnostic Tests	231
15.4.1	Screening Tests	231
15.4.2	Enzyme Assays	232
15.4.3	Histopathological Studies	234
15.4.4	Magnetic Resonance Imaging (MRI) and Spectroscopy of Muscle and Brain	234
15.4.5	Molecular Genetic Tests	234
15.5	Treatment and Prognosis	235
	References	236
16	Creatine Deficiency Syndromes	239
	<i>Sylvia Stöckler-Ipsiroglu, Saadet Mercimek-Mahmutoglu, Gajja S. Salomons</i>	
16.1	Clinical Presentation	241
16.1.1	Guanidinoacetate Methyltransferase Deficiency	241
16.1.2	Arginine: Glycine Amidinotransferase Deficiency	241
16.1.3	SLC6A8 Deficiency	241
16.2	Metabolic Derangement	242
16.3	Genetics	243
16.4	Diagnostic Tests	243
16.4.1	MRS of Brain	243
16.4.2	Metabolite Screening	243
16.4.3	DNA Diagnostics	244
16.4.4	Functional Tests/Enzymatic Diagnostics	244
16.4.5	Prenatal Diagnosis	244
16.5	Treatment and Prognosis	244
16.5.1	GAMT Deficiency	244

16.5.2	AGAT Deficiency	244
16.5.3	SLC6A8 Deficiency	245
	References	245

IV Disorders of Amino Acid Metabolism and Transport

17	Hyperphenylalaninaemia	251
	<i>John H. Walter, Robin H. Lachmann, Peter Burgard</i>	
17.1	Introduction	253
17.2	Phenylalanine Hydroxylase Deficiency	253
17.2.1	Clinical Presentation	253
17.2.2	Metabolic Derangement	253
17.2.3	Genetics	253
17.2.4	Diagnostic Tests	254
17.2.5	Treatment and Prognosis	254
17.3	Maternal PKU	258
17.3.1	Clinical Presentation	258
17.3.2	Metabolic Derangement	258
17.3.3	Treatment and Prognosis	259
17.4	HPA and Disorders of Bipterin Metabolism	260
17.4.1	Clinical Presentation	260
17.4.2	Metabolic Derangement	260
17.4.3	Genetics	261
17.4.4	Diagnostic and Confirmatory Tests	261
17.4.5	Treatment and Prognosis	262
	References	263
18	Disorders of Tyrosine Metabolism	265
	<i>Anupam Chakrapani, Paul Gissen, Patrick McKiernan</i>	
18.1	Hereditary Tyrosinaemia Type I (Hepatorenal Tyrosinaemia)	267
18.1.1	Clinical Presentation	267
18.1.2	Metabolic Derangement	267
18.1.3	Genetics	268
18.1.4	Diagnostic Tests	268
18.1.5	Treatment and Prognosis	269
18.2	Hereditary Tyrosinaemia Type II (Oculocutaneous Tyrosinaemia, Richner-Hanhart Syndrome)	271
18.2.1	Clinical Presentation	271
18.2.2	Metabolic Derangement	271
18.2.3	Genetics	271
18.2.4	Diagnostic Tests	271
18.2.5	Treatment and Prognosis	272
18.3	Hereditary Tyrosinaemia Type III	272
18.3.1	Clinical Presentation	272
18.3.2	Metabolic Derangement	272
18.3.3	Genetics	272
18.3.4	Diagnostic Tests	272

18.3.5	Treatment and Prognosis	272	20.1.2	Presentation in Infants	299
18.4	Transient Tyrosinaemia	273	20.1.3	Presentation in Older Children and Adults	300
18.5	Alkaptonuria	273	20.1.4	Newborn Screening	300
18.5.1	Clinical Presentation	273	20.2	Metabolic Derangement	301
18.5.2	Metabolic Derangement	273	20.2.1	The Urea Cycle, Its Connections and Regulation	301
18.5.3	Genetics	274	20.2.2	Sources of Ammonia and Inter-organ Fluxes	301
18.5.4	Diagnostic Tests	274	20.2.3	CNS Toxicity in Urea Cycle Defects	301
18.5.5	Treatment and Prognosis	274	20.3	Genetics of Urea Cycle Defects	302
18.6	Hawkinsinuria	274	20.4	Prenatal Diagnosis	303
18.6.1	Clinical Presentation	274	20.5	Diagnostic Tests and Differential Diagnosis	303
18.6.2	Metabolic Derangement	274	20.6	Treatment	304
18.6.3	Genetics	274	20.6.1	Treatment in Acute Presentations	304
18.6.4	Diagnostic Tests	274	20.6.2	Maintenance Therapy	306
18.6.5	Treatment and Prognosis	275	20.7	Outcome	308
	References	275	20.8	Pregnancy	308
				References	309
19	Branched-chain Organic Acidurias/ Acidaemias	277	21	Disorders of Sulfur Amino Acid Metabolism	311
	<i>Hélène Ogier de Baulhy, Carlo Dionisi-Vici, Udo Wendel</i>			<i>Generoso Andria, Brian Fowler, Gianfranco Sebastio</i>	
19.1	Maple Syrup Urine Disease, Isovaleric Aciduria, Propionic Aciduria, Methylmalonic Aciduria	279	21.1	Homocystinuria Due to Cystathionine β -Synthase Deficiency	313
19.1.1	Clinical Presentation	279	21.1.1	Clinical Presentation	313
19.1.2	Metabolic Derangement	281	21.1.2	Metabolic Derangement	314
19.1.3	Genetics	283	21.1.3	Genetics	314
19.1.4	Diagnostic Tests	284	21.1.4	Diagnostic Tests	315
19.1.5	Treatment and Prognosis	284	21.1.5	Treatment and Prognosis	316
19.2	3-Methylcrotonyl Glycinuria	289	21.2	Methionine S-Adenosyltransferase Deficiency	317
19.2.1	Clinical Presentation	289	21.2.1	Clinical Presentation	317
19.2.2	Metabolic Derangement	290	21.2.2	Metabolic Derangement	317
19.2.3	Genetics	290	21.2.3	Genetics	317
19.2.4	Diagnostic Tests	290	21.2.4	Diagnostic Tests	318
19.2.5	Treatment and Prognosis	290	21.2.5	Treatment and Prognosis	318
19.3	3-Methylglutaconic Aciduria	291	21.3	Glycine N-Methyltransferase Deficiency	318
19.4	Short-/Branched-chain Acyl-CoA Dehydrogenase Deficiency	292	21.3.1	Clinical Presentation	318
19.5	2-Methyl-3-Hydroxybutyryl-CoA Dehydrogenase Deficiency	292	21.3.2	Metabolic Derangement	318
19.6	Isobutyryl-CoA Dehydrogenase Deficiency	292	21.3.3	Genetics	318
19.7	3-Hydroxyisobutyric Aciduria	292	21.3.4	Diagnostic Tests	318
19.8	Malonic Aciduria	293	21.3.5	Treatment and Prognosis	318
19.8.1	Clinical Presentation	293	21.4	S-Adenosylhomocysteine Hydrolase Deficiency	318
19.8.2	Metabolic Derangement	293	21.4.1	Clinical Presentation	318
19.8.3	Genetics	293	21.4.2	Metabolic Derangement	319
19.8.4	Diagnostic Tests	293	21.4.3	Genetics	319
19.8.5	Treatment and Prognosis	293	21.4.4	Diagnostic Tests	319
	References	293	21.4.5	Treatment and Prognosis	319
20	Disorders of the Urea Cycle and Related Enzymes	297	21.5	γ -Cystathioninase Deficiency	319
	<i>Frits A. Wijburg, Marie-Cécile Nassogne</i>		21.5.1	Clinical Presentation	319
20.1	Clinical Presentation	299	21.5.2	Metabolic Derangement	319
20.1.1	Neonatal Presentation	299	21.5.3	Genetics	319
			21.5.4	Diagnostic Tests	319
			21.5.5	Treatment and Prognosis	319
			21.6	Isolated Sulfite Oxidase Deficiency	319

21.6.1	Clinical Presentation	319	23.5.1	Clinical Presentation	337
21.6.2	Metabolic Derangement	320	23.5.2	Metabolic Derangement	339
21.6.3	Genetics	320	23.5.3	Genetics	339
21.6.4	Diagnostic Tests	320	23.5.4	Diagnostic Tests	340
21.6.5	Treatment and Prognosis	320	23.5.5	Treatment and Prognosis	340
	References	320	23.6	Glutaric Aciduria Type III	342
22	Disorders of Ornithine Metabolism	323	23.6.1	Clinical Presentation	342
	<i>Matthias R. Baumgartner, David Valle</i>		23.6.2	Metabolic Derangement	342
22.1	Hyperornithinaemia Due to Ornithine Aminotransferase Deficiency (Gyrate Atrophy of the Choroid and Retina)	325	23.6.3	Genetics	342
22.1.1	Clinical Presentation	325	23.6.4	Diagnostic Tests	342
22.1.2	Metabolic Derangement	326	23.6.5	Treatment and Prognosis	342
22.1.3	Genetics	326	23.7	L-2-Hydroxyglutaric Aciduria	342
22.1.4	Diagnostic Tests	326	23.7.1	Clinical Presentation	342
22.1.5	Treatment and Prognosis	327	23.7.2	Metabolic Derangement	342
22.2	Hyperornithinaemia, Hyperammonaemia and Homocitrullinuria (HHH) Syndrome	328	23.7.3	Genetics	342
22.2.1	Clinical Presentation	328	23.7.4	Diagnostic Tests	343
22.2.2	Metabolic Derangement	328	23.7.5	Treatment and Prognosis	343
22.2.3	Genetics	328	23.8	D-2-Hydroxyglutaric Aciduria	343
22.2.4	Diagnostic Tests	329	23.8.1	Clinical Presentation	343
22.2.5	Treatment and Prognosis	329	23.8.2	Metabolic Derangement	344
22.3	Δ^1 -Pyrroline-5-Carboxylate Synthase Deficiency	329	23.8.3	Genetics	344
22.3.1	Clinical Presentation	329	23.8.4	Diagnostic Tests	344
22.3.2	Metabolic Derangement	330	23.8.5	Treatment and Prognosis	344
22.3.3	Genetics	330	23.9	N-Acetylaspartic Aciduria (Canavan Disease)	345
22.3.4	Diagnostic Tests	330	23.9.1	Clinical Presentation	345
22.3.5	Treatment and Prognosis	330	23.9.2	Metabolic Derangement	345
22.4	Δ^1 -Pyrroline-5-Carboxylate Reductase Deficiency	330	23.9.3	Genetics	345
	References	330	23.9.4	Diagnostic Tests	345
			23.9.5	Treatment and Prognosis	345
23	Cerebral Organic Acid Disorders and Other Disorders of Lysine Catabolism	333	23.10	Hypoacetylaspartia	346
	<i>Georg F. Hoffmann, Stefan Kölker</i>			References	346
23.1	Introduction	335	24	Nonketotic Hyperglycinaemia (Glycine Encephalopathy)	349
23.2	Hyperlysinaemia/Saccharopinuria	336		<i>Olivier Dulac, Marie-Odile Rolland</i>	
23.2.1	Clinical Presentation	336	24.1	Clinical Presentation	350
23.2.2	Metabolic Derangement	336	24.1.1	Neonatal NKH	350
23.2.3	Genetics	336	24.1.2	Late-onset NKH	352
23.2.4	Diagnostic Tests	336	24.2	Metabolic Derangement	352
23.2.5	Treatment and Prognosis	337	24.3	Genetics	353
23.3	Hydroxylysinuria	337	24.4	Diagnostic Tests	353
23.4	2-Amino-/2-Oxadipic Aciduria	337	24.5	Differential Diagnosis	354
23.4.1	Clinical Presentation	337	24.6	Prenatal Diagnosis	354
23.4.2	Metabolic Derangement	337	24.7	Treatment	354
23.4.3	Genetics	337		References	354
23.4.4	Diagnostic Tests	337	25	Disorders of Proline and Serine Metabolism	357
23.4.5	Treatment and Prognosis	337		<i>Jaak Jaeken</i>	
23.5	Glutaric Aciduria Type I	337	25.1	Inborn Errors of Proline Metabolism	359
			25.1.1	Proline Oxidase Deficiency (Hyperprolinaemia Type I)	359

25.1.2	Δ^1 -Pyrroline 5-Carboxylate Dehydrogenase Deficiency (Hyperprolinaemia Type II)	359	27.3.3	Biotin-responsive Basal Ganglia Disease	379
25.1.3	Δ^1 -Pyrroline 5-Carboxylate Reductase Deficiency	360	27.4	Diagnostic Tests	380
25.2	Inborn Errors of Serine Metabolism	360	27.4.1	Holocarboxylase Synthetase Deficiency	380
25.2.1	3-Phosphoglycerate Dehydrogenase Deficiency	360	27.4.2	Biotinidase Deficiency	380
25.2.2	Phosphoserine Aminotransferase Deficiency	361	27.4.3	Acquired Biotin Deficiency	380
25.2.3	Phosphoserine Phosphatase Deficiency	361	27.4.4	Prenatal Diagnosis	380
25.2.4	Serine Deficiency with Ichthyosis and Polyneuropathy	361	27.5	Treatment and Prognosis	381
25.2.5	Serine Palmitoyltransferase Defects	361	27.5.1	Holocarboxylase Synthetase Deficiency	381
	References	361	27.5.2	Biotinidase Deficiency	381
			27.5.3	Biotin-responsive Basal Ganglia Disease	382
				References	382
26	Transport Defects of Amino Acids at the Cell Membrane: Cystinuria, Lysinuric Protein Intolerance and Hartnup Disorder	363	28	Disorders of Cobalamin and Folate Transport and Metabolism	385
	<i>Kirsti Nääntö-Salonen, Harri Niinikoski, Olli G. Simell</i>			<i>David Watkins, David S. Rosenblatt, Brian Fowler</i>	
26.1	Cystinuria	364	28.1	Disorders of Absorption and Transport of Cobalamin	387
26.1.1	Clinical Presentation	364	28.1.1	Hereditary Intrinsic Factor Deficiency	387
26.1.2	Metabolic Derangement	365	28.1.2	Defective Transport of Cobalamin by Enterocytes (Imerslund-Gräsbeck Syndrome)	387
26.1.3	Genetics	365	28.1.3	Haptocorrin (R Binder) Deficiency	388
26.1.4	Diagnostic Tests	365	28.1.4	Transcobalamin Deficiency	388
26.1.5	Treatment and Prognosis	365	28.1.5	Transcobalamin Receptor Deficiency	389
26.2	Lysinuric Protein Intolerance	366	28.2	Disorders of Intracellular Utilisation of Cobalamin	389
26.2.1	Clinical Presentation	366	28.2.1	Combined Deficiencies of Adenosylcobalamin and Methylcobalamin	390
26.2.2	Metabolic Derangement	367	28.2.2	Adenosylcobalamin Deficiency	392
26.2.3	Genetics	367	28.2.3	Methylcobalamin Deficiency	393
26.2.4	Diagnostic Tests	367	28.3	Disorders of Absorption and Metabolism of Folate	395
26.2.5	Treatment and Prognosis	367	28.3.1	Hereditary Folate Malabsorption	395
26.3	Hartnup Disorder	368	28.3.2	Cerebral Folate Deficiency	395
26.3.1	Clinical Presentation	368	28.3.3	Glutamate-Formiminotransferase Deficiency	396
26.3.2	Metabolic Derangement	368	28.3.4	Methylenetetrahydrofolate Reductase Deficiency	396
26.3.3	Genetics	369	28.3.5	Dihydrofolate Reductase Deficiency	397
26.3.4	Diagnostic Tests	369		References	398
26.3.5	Treatment and Prognosis	369			
26.4	Asymptomatic Aminoacidurias	369			
	References	370			

V Vitamin-Responsive Disorders

27	Biotin-responsive Disorders	375
	<i>Matthias R. Baumgartner, Terttu Suormala</i>	
27.1	Clinical Presentation	377
27.1.1	Holocarboxylase Synthetase Deficiency	377
27.1.2	Biotinidase Deficiency	377
27.1.3	Biotin-responsive Basal Ganglia Disease	378
27.2	Metabolic Derangement	378
27.3	Genetics	379
27.3.1	Holocarboxylase Synthetase Deficiency	379
27.3.2	Biotinidase Deficiency	379

VI Neurotransmitter and Small Peptide Disorders

29	Disorders of Neurotransmission	405
	<i>Ángels García-Cazorla, K. Michael Gibson, Peter T. Clayton</i>	
29.1	Inborn Errors of Gamma Amino Butyric Acid Metabolism	407
29.1.1	Gamma Amino Butyric Acid Transaminase Deficiency	407

29.1.2	Succinic Semialdehyde Dehydrogenase Deficiency	407
29.1.3	Homocarnosinosis	408
29.2	Inborn Defects of Receptors and Transporters of Neurotransmitters	408
29.2.1	Hyperekplexia	408
29.2.2	GABA Receptor Mutations	410
29.2.3	Mitochondrial Glutamate Transporter Defect	410
29.3	Inborn Errors of Monoamine Metabolism	412
29.3.1	Tyrosine Hydroxylase Deficiency	412
29.3.2	Aromatic L-Aminoacid Decarboxylase Deficiency	412
29.3.3	Dopamine β -Hydroxylase Deficiency	413
29.3.4	Monoamine Oxidase-A Deficiency	413
29.3.5	Guanosine Triphosphate Cyclohydrolase-I Deficiency	414
29.3.6	Sepiapterine Reductase Deficiency	415
29.3.7	Dopamine Transporter Defect	415
29.3.8	Other Inborn Defects Involved in Monoamine Metabolism	415
29.4	Inborn Disorders Involving Pyridoxine and Pyridoxal Phosphate	417
29.4.1	Pyridoxine-responsive Epilepsy	417
29.4.2	Pyridox(am)ine 5'-Phosphate Oxidase Deficiency	419
	References	420
30	Disorders in the Metabolism of Glutathione and Imidazole Dipeptides	423
	<i>Ertan Mayatepek, Jaak Jaeken</i>	
30.1	Disorders in the Metabolism of Glutathione	425
30.1.1	γ -Glutamylcysteine Synthetase Deficiency	425
30.1.2	Glutathione Synthetase Deficiency	425
30.1.3	γ -Glutamyl Transpeptidase Deficiency	427
30.1.4	5-Oxoprolinase Deficiency	427
30.1.5	Dipeptidase Deficiency	428
30.1.6	Secondary 5-Oxoprolinuria	428
30.2	Disorders of Imidazole Dipeptides	428
30.2.1	Serum Carnosinase Deficiency	428
30.2.2	Homocarnosinosis	429
30.2.3	Prolidase Deficiency	429
	References	430
31	Trimethylaminuria and Dimethylglycine Dehydrogenase Deficiency	431
	<i>Valerie Walker, Ron A. Wevers</i>	
31.1	Trimethylaminuria (Fish Odour Syndrome)	433
31.1.1	Clinical Presentation	433
31.1.2	Metabolic Derangement	433
31.1.3	Genetics	433
31.1.4	Diagnostic Tests	433
31.1.5	Treatment	433

31.2	Dimethylglycine Dehydrogenase Deficiency	434
31.2.1	Clinical Presentation	434
31.2.2	Metabolic Derangement	434
31.2.3	Genetics	434
31.2.4	Diagnostic Tests	434
31.2.5	Treatment	434
	References	434

VII Disorders of Lipid and Bile Acid Metabolism

32	Dyslipidaemias	439
	<i>Annabelle Rodriguez-Oquendo, Peter O. Kwiterovich, Jr.</i>	
32.1	Overview of Plasma Lipid and Lipoprotein Metabolism	441
32.1.1	Exogenous Lipoprotein Metabolism	442
32.1.2	Endogenous Lipoprotein Metabolism	442
32.1.3	Reverse Cholesterol Transport and High-density Lipoproteins	443
32.2	Disorders of Exogenous Lipoprotein Metabolism	445
32.2.1	Lipoprotein Lipase Deficiency	445
32.2.2	Apo C-II Deficiency	446
32.3	Disorders of Endogenous Lipoprotein Metabolism	446
32.3.1	Disorders of VLDL Overproduction	446
32.3.2	Disorders of LDL Removal	448
32.4	Disorders of Endogenous and Exogenous Lipoprotein Transport	450
32.4.1	Dysbetalipoproteinaemia (Type III Hyperlipoproteinaemia)	450
32.4.2	Hepatic Lipase Deficiency	451
32.5	Disorders of Reduced LDL-Cholesterol Levels	451
32.5.1	Abetalipoproteinaemia	451
32.5.2	Hypobetalipoproteinaemia	451
32.5.3	Chylomicron Retention Disease	452
32.6	Disorders of Reverse Cholesterol Transport	452
32.6.1	Familial Hypoalphalipoproteinaemia	452
32.6.2	Apolipoprotein A-I Mutations	452
32.6.3	Tangier Disease	453
32.6.4	Lecithin-cholesterol Acyltransferase Deficiency	453
32.6.5	Cholesteryl Ester Transfer Protein Deficiency	453
32.6.6	Scavenger Receptor Class B Type I Receptor Deficiency	453
32.6.7	Deficiency of Endothelial Lipase	454
32.6.8	Elevated Lipoprotein(a)	454
32.7	Guidelines for the Clinical Evaluation and Treatment of Dyslipidaemia	454
32.7.1	Clinical Evaluation	454

32.7.2	Dietary Treatment, Weight Reduction and Exercise	455	33.6.5	Treatment and Prognosis	468
32.7.3	Goals for Dietary and Hygienic Therapy	455	33.7	Hydrops – Ectopic Calcification – Moth-eaten (HEM) Skeletal Dysplasia or Greenberg Skeletal Dysplasia (Sterol $\Delta 14$ -Reductase Deficiency)	468
32.7.4	Low-density-Lipoprotein-lowering Drugs	456	33.7.1	Clinical Presentation	468
32.7.5	Triglyceride-lowering Drugs	458	33.7.2	Metabolic Derangement	468
32.7.6	Combination Pharmacotherapy	458	33.7.3	Genetics	469
32.8	Abbreviations	458	33.7.4	Diagnostic Tests	469
	References	458	33.7.5	Treatment and Prognosis	469
33	Disorders of Cholesterol Synthesis	461	33.8	Other Disorders	469
	<i>Hans R. Waterham, Peter T. Clayton</i>			References	469
33.1	Mevalonate Kinase Deficiency	463	34	Disorders of Bile Acid Synthesis	473
33.1.1	Clinical Presentation	463		<i>Peter T. Clayton</i>	
33.1.2	Metabolic Derangement	463	34.1	Introduction	475
33.1.3	Genetics	463	34.2	3β -Hydroxy- $\Delta 5$ -C27-Steroid Dehydrogenase Deficiency	475
33.1.4	Diagnostic Tests	464	34.2.1	Clinical Presentation	475
33.1.5	Treatment and Prognosis	464	34.2.2	Metabolic Derangement	475
33.2	Smith-Lemli-Opitz Syndrome (7-Dehydrocholesterol Reductase Deficiency) ...	464	34.2.3	Genetics	476
33.2.1	Clinical Presentation	464	34.2.4	Diagnostic Tests	476
33.2.2	Metabolic Derangement	464	34.2.5	Treatment and Prognosis	476
33.2.3	Genetics	465	34.3	$\Delta 4$ -3-Oxosteroid 5β -Reductase Deficiency	477
33.2.4	Diagnostic Tests	465	34.3.1	Clinical Presentation	477
33.2.5	Treatment and Prognosis	465	34.3.2	Metabolic Derangement	477
33.3	X-Linked Dominant Chondrodysplasia Punctata 2 or Conradi-Hünermann Syndrome (Sterol $\Delta 8$ - $\Delta 7$ Isomerase Deficiency)	465	34.3.3	Genetics	477
33.3.1	Clinical Presentation	465	34.3.4	Diagnostic Tests	477
33.3.2	Metabolic Derangement	466	34.3.5	Treatment and Prognosis	478
33.3.3	Genetics	466	34.4	Cerebrotendinous Xanthomatosis (Sterol 27-Hydroxylase Deficiency)	478
33.3.4	Diagnostic Tests	466	34.4.1	Clinical Presentation	478
33.3.5	Treatment and Prognosis	466	34.4.2	Metabolic Derangement	478
33.4	CHILD Syndrome (3β -Hydroxysteroid C-4 Dehydrogenase Deficiency)	466	34.4.3	Genetics	479
33.4.1	Clinical Presentation	466	34.4.4	Diagnostic Tests	479
33.4.2	Metabolic Derangement	466	34.4.5	Treatment and Prognosis	479
33.4.3	Genetics	467	34.5	α -Methylacyl-CoA Racemase Deficiency	479
33.4.4	Diagnostic Tests	467	34.5.1	Clinical Presentation	479
33.4.5	Treatment and Prognosis	467	34.5.2	Metabolic Derangement	480
33.5	Desmosterolosis (Desmosterol Reductase Deficiency)	467	34.5.3	Genetics	480
33.5.1	Clinical Presentation	467	34.5.4	Diagnostic Tests	480
33.5.2	Metabolic Derangement	467	34.5.5	Treatment and Prognosis	480
33.5.3	Genetics	467	34.6	Oxysterol 7α -Hydroxylase Deficiency	480
33.5.4	Diagnostic Tests	467	34.6.1	Clinical Presentation	480
33.5.5	Treatment and Prognosis	467	34.6.2	Metabolic Derangement	480
33.6	Lathosterolosis (Sterol $\Delta 5$ -Desaturase Deficiency)	468	34.6.3	Genetics	480
33.6.1	Clinical Presentation	468	34.6.4	Diagnostic Tests	481
33.6.2	Metabolic Derangement	468	34.6.5	Treatment and Prognosis	481
33.6.3	Genetics	468	34.7	Bile Acid Amidation Defect 1: Bile Acid CoA: Amino Acid N-Acyl Transferase Deficiency	481
33.6.4	Diagnostic Tests	468	34.7.1	Clinical Presentation	481
			34.7.2	Metabolic Derangement	481
			34.7.3	Genetics	481

34.7.4	Diagnostic Tests	481	36.1.2	Phosphoribosyl Pyrophosphate Synthetase Deficiency	502
34.7.5	Treatment and Prognosis	481	36.1.3	Adenylosuccinase (Adenylosuccinate Lyase) Deficiency	502
34.8	Bile Acid Amidation Defect 2: Bile Acid CoA Ligase Deficiency	481	36.1.4	AICA-Ribosiduria (ATIC Deficiency)	503
34.8.1	Clinical Presentation	481	36.1.5	Muscle Adenosine Monophosphate Deaminase Deficiency	503
34.8.2	Metabolic Derangement	482	36.1.6	Adenylate Kinase 2 Deficiency	504
34.8.3	Genetics	482	36.1.7	Adenosine Deaminase Deficiency	504
34.8.4	Diagnostic Tests	482	36.1.8	Adenosine Deaminase Superactivity	506
34.8.5	Treatment and Prognosis	482	36.1.9	Purine Nucleoside Phosphorylase Deficiency	506
34.9	Cholesterol 7 α -Hydroxylase Deficiency	482	36.1.10	Xanthine Oxidase Deficiency	506
34.9.1	Clinical Presentation	482	36.1.11	Hypoxanthine-guanine Phosphoribosyl-transferase Deficiency	507
34.9.2	Metabolic Derangement	482	36.1.12	Adenine Phosphoribosyltransferase Deficiency	509
34.9.3	Genetics	482	36.1.13	Deoxyguanosine Kinase Deficiency	509
34.9.4	Diagnostic Tests	482	36.1.14	Thiopurine Methyltransferase Deficiency	509
34.9.5	Treatment and Prognosis	483	36.1.15	Inosine Triphosphatase Deficiency	510
34.10	Disorders of Peroxisome Biogenesis and Peroxisomal- β -Oxidation	483	36.2	Inborn Errors of Pyrimidine Metabolism	512
	References	483	36.2.1	UMP Synthase Deficiency (Hereditary Orotic Aciduria)	512
35	Disorders of Phospholipid and Glycosphingolipid Synthesis	485	36.2.2	Miller Syndrome	512
	<i>Foudil Lamari, Frédéric Sédal, Jean-Marie Saudubray</i>		36.2.3	Dihydropyrimidine Dehydrogenase Deficiency	513
35.1	Disorders of Phospholipid Synthesis	487	36.2.4	Dihydropyrimidinase Deficiency	513
35.1.1	LIPN1 Deficiency (Phosphatidate Phosphatase 1 Deficiency)	487	36.2.5	Ureidopropionase Deficiency	514
35.1.2	Cardiolipin Remodelling Enzyme Deficiency: Barth Syndrome	488	36.2.6	Pyrimidine 5'-Nucleotidase Deficiency	514
35.1.3	Phospholipase A2 Deficiency (Infantile Neuroaxonal Dystrophy and Neurodegeneration with Brain Iron Accumulation)	489	36.2.7	Cytosolic 5'-Nucleotidase Superactivity	514
35.1.4	α - β -Hydrolase 12 (ABHD12) Deficiency (Polyneuropathy, Hearing Loss, Ataxia, Retinitis Pigmentosa and Cataracts: PHARC Syndrome) ..	490	36.2.8	Thymidine Phosphorylase Deficiency	514
35.2	Disorders of Glycosphingolipid Synthesis	493	36.2.9	Cytidine Deaminase Deficiency	514
35.2.1	Serine Palmitoyl CoA Transferase Deficiency	493	36.2.10	Thymidine Kinase 2 Deficiency	515
35.2.2	Fatty Acid 2-Hydroxylase Deficiency	494		References	515
35.2.3	GM3 Synthase Deficiency	494	37	Disorders of Haem Biosynthesis	519
	References	494		<i>Charles Marquez Lourenço, Chul Lee, Karl E. Anderson</i>	
VIII Disorders of Nucleic Acid and Heme Metabolism					
36	Disorders of Purine and Pyrimidine Metabolism	499	37.1	X-Linked Sideroblastic Anaemia	521
	<i>Georges van den Berghe, M.-Françoise Vincent, Sandrine Marie</i>		37.2	The Porphyrias	521
36.1	Inborn Errors of Purine Metabolism	501	37.2.1	Classification and Diagnosis	522
36.1.1	Phosphoribosyl Pyrophosphate Synthetase Superactivity	501	37.3	5-Aminolevulinic Acid Dehydratase Porphyria	523
			37.4	Acute Intermittent Porphyria	524
			37.5	Congenital Erythropoietic Porphyria (Gunther Disease)	525
			37.6	Porphyria Cutanea Tarda	526
			37.7	Hepatoerythropoietic Porphyria	528
			37.8	Hereditary Coproporphyria and Variegate Porphyria	528
			37.9	Erythropoietic Protoporphyria	529
				References	531

IX Disorders of Metal Transport

38 Disorders in the Transport of Copper, Iron, Magnesium, Manganese, Selenium and Zinc	535
<i>Marc Bierings, Peter Clayton, Roderick H.J. Houwen</i>	
38.1 Copper	537
38.1.1 Wilson Disease	537
38.1.2 Menkes Disease	539
38.1.3 Other Copper Storage Disorders	540
38.2 Iron	542
38.2.1 Systemic Iron Overload Syndromes (Haemochromatosis)	542
38.2.2 Neurodegeneration with Brain Iron Accumulation (NBIA)	543
38.2.3 Iron Deficiency Syndromes	544
38.3 Magnesium	544
38.3.1 Primary Hypomagnesaemia with Secondary Hypocalcaemia	545
38.3.2 Hypomagnesaemia with Hypercalciuria and Nephrocalcinosis	545
38.3.3 Isolated Dominant Hypomagnesaemia	546
38.3.4 Isolated Autosomal Recessive Hypomagnesaemia	546
38.4 Manganese	546
38.4.1 Isolated Autosomal Recessive Hypermanganesaemia	547
38.4.2 Disorders Affecting Calcium/Manganese Transporters	547
38.5 Selenium	547
38.6 Zinc	548
38.6.1 Acrodermatitis Enteropathica	548
38.6.2 Zinc Deficiency in Breastfed Babies	549
38.6.3 Hyperzincaemia with Hypercalprotectinaemia	549
38.6.4 Autosomal Dominant Hyperzincaemia Without Symptoms	549
References	549

X Organelle-Related Disorders: Lysosomes, Peroxisomes, and Golgi and Pre-Golgi Systems

39 Disorders of Sphingolipid Metabolism and Neuronal Ceroid-Lipofuscinoses	555
<i>Marie T. Vanier, Catherine Caillaud</i>	
39.1 Gaucher Disease	557
39.1.1 Clinical Presentation	557
39.1.2 Metabolic Derangement	558
39.1.3 Genetics	558
39.1.4 Diagnostic Tests	558
39.1.5 Treatment and Prognosis	558
39.2 Acid Sphingomyelinase-deficient Niemann-Pick Disease (Type A, Type B and Intermediate Forms)	559
39.2.1 Clinical Presentation	559
39.2.2 Metabolic Derangement	560
39.2.3 Genetics	560
39.2.4 Diagnostic Tests	560
39.2.5 Treatment and Prognosis	560
39.3 GM1 Gangliosidosis	561
39.3.1 Clinical Presentation	561
39.3.2 Metabolic Derangement	561
39.3.3 Genetics	562
39.3.4 Diagnostic Tests	562
39.3.5 Treatment and Prognosis	562
39.4 GM2 Gangliosidosis	562
39.4.1 Clinical Presentation	562
39.4.2 Metabolic Derangement	562
39.4.3 Genetics	563
39.4.4 Diagnostic Tests	563
39.4.5 Treatment	563
39.5 Krabbe Disease	563
39.5.1 Clinical Presentation	563
39.5.2 Metabolic Derangement	564
39.5.3 Genetics	564
39.5.4 Diagnostic Tests	564
39.5.5 Treatment	565
39.6 Metachromatic Leukodystrophy	565
39.6.1 Clinical Presentation	565
39.6.2 Metabolic Derangement	565
39.6.3 Genetics	565
39.6.4 Diagnostic Tests	565
39.6.5 Treatment and Prognosis	566
39.7 Fabry Disease	566
39.7.1 Clinical Presentation	566
39.7.2 Metabolic Derangement	567
39.7.3 Genetics	567
39.7.4 Diagnostic Tests	567
39.7.5 Treatment and Prognosis	567
39.8 Farber Disease	568
39.8.1 Clinical Presentation	568
39.8.2 Metabolic Derangement and Genetics	568
39.8.3 Diagnostic Tests	568
39.8.4 Treatment and Prognosis	568
39.9 Prosaposin Deficiency	568
39.9.1 Clinical Presentation	568
39.9.2 Metabolic Derangement and Genetics	568
39.9.3 Diagnostic Tests	568
39.10 Niemann-Pick Disease Type C	569

39.10.1	Clinical Presentation	569	42	Congenital Disorders of Glycosylation	607
39.10.2	Metabolic Derangement	569		<i>Jaak Jaeken</i>	
39.10.3	Genetics	570	42.1	Introduction	608
39.10.4	Diagnostic Tests	570	42.2	Congenital Disorders of Protein	
39.10.5	Treatment and Prognosis	570		<i>N-Glycosylation</i>	<i>612</i>
39.11	Disorders of Sphingolipid Synthesis	571	42.2.1	Phosphomannomutase-2 Deficiency	
39.12	Neuronal Ceroid Lipofuscinoses	571		(PMM2-CDG)	612
39.12.1	Clinical Presentation	571	42.2.2	Phosphomannose-Isomerase Deficiency	
39.12.2	Metabolic Derangement	572		(MPI-CDG)	613
39.12.3	Genetics	572	42.2.3	Glucosyltransferase I Deficiency (ALG6-CDG) ...	613
39.12.4	Diagnostic Tests	572	42.3	Congenital Disorders of Protein	
39.12.5	Treatment and Prognosis	573		<i>O-Glycosylation</i>	<i>614</i>
	References	574	42.3.1	Hereditary Multiple Exostoses	
				(EXT1/EXT2-CDG)	614
40	Mucopolysaccharidoses and		42.3.2	Walker-Warburg Syndrome	
	Oligosaccharidoses	579		(POMT1/POMT2-CDG)	614
	<i>J. Ed Wraith</i>		42.3.3	Muscle-eye-brain Disease (POMGNT1-CDG) ...	615
40.1	Clinical Presentation	581	42.4	Defects in Lipid Glycosylation	615
40.1.1	Mucopolysaccharidoses	581	42.4.1	GM3 Synthase Deficiency (ST3GAL5-CDG)	615
40.1.2	Oligosaccharidoses	587	42.5	Defects in Multiple Glycosylation Pathways	
40.2	Metabolic Derangements	588		and in Other Pathways	615
40.3	Genetics	588	42.5.1	Hereditary Inclusion Body Myopathy	
40.4	Diagnostic Tests	588		(GNE-CDG)	615
40.5	Treatment and Prognosis	589	42.5.2	COG7 Deficiency	615
	References	589	42.5.3	ATP6V0A2 (Autosomal Recessive Cutis	
				Laxa Type 2)	615
				References	616
41	Peroxisomal Disorders	591	43	Cystinosis	617
	<i>Bwee Tien Poll-The, Patrick Aubourg,</i>			<i>Michel Broyer, Patrick Niaudet</i>	
	<i>Ronald J.A. Wanders</i>		43.1	Infantile Cystinosis	618
41.1	Clinical Presentation	593	43.1.1	Clinical Presentation	618
41.1.1	The Neonatal Period	594	43.1.2	Metabolic Derangement	620
41.1.2	The First 6 Months of Life	595	43.1.3	Genetics	620
41.1.3	Between 6 Months and 4 Years	595	43.1.4	Diagnostic Tests	621
41.1.4	Beyond 4 Years of Age	596	43.1.5	Treatment	621
41.2	Metabolic Derangements	597	43.2	Intermediate Cystinosis	622
41.2.1	Defects of Peroxisome Biogenesis	599	43.3	Ocular Cystinosis	622
41.2.2	Deficiencies of Single Peroxisomal Enzymes ...	599		References	622
41.3	Genetics	601			
41.4	Diagnostic Tests	601			
41.4.1	Diagnostic Group 1	601			
41.4.2	Diagnostic Group 2	602			
41.4.3	Diagnostic Group 3	602			
41.4.4	Diagnostic Group 4	602			
41.4.5	Histological Detection	602			
41.4.6	Prenatal Diagnosis	603			
41.5	Treatment and Prognosis	603			
	References	603			
				Appendix A: Medications Used in the	
				Treatment of Inborn Errors	625
				<i>JH Walter and JE Wraith</i>	
				Subject Index	633